Caring for Australians and <scp>New ZealandeRs</scp> with kidney <scp>Impairment</scp> guideline commentary on kidney disease: improving global outcomes 2025 guidelines for diagnosis and management of autosomal polycystic kidney disease

Autosomal polycystic kidney disease (ADPKD) is the most common form of inherited kidney disease. The international guideline developer, Kidney Disease: Improving Global Outcomes (KDIGO), published a 2025 clinical practice guideline reflecting advances in genetic testing and the first disease-modifying agent, tolvaptan. However, KDIGO guidelines do not address healthcare access or equity issues relevant to the needs of our populations in Australia and New Zealand. The Caring for Australians and New ZealandeRs with kidney Impairment (CARI) Guidelines Working Group has provided a regional commentary to contextualise the KDIGO 2025 ADPKD guideline. This commentary aims to support clinicians in applying the KDIGO ADPKD 2025 guidance within our local health systems and highlights challenges in the implementation, including public subsidy limitations for recommended genetic testing and treatments. It also addresses equity concerns such as rural and remoteness, ensuring guidance is relevant to Australia and New Zealand.

Authors

Institutions

Publication Details

Journal
Internal Medicine Journal
Published
2026-04-21
DOI
https://doi.org/10.1111/imj.70411
Primary Topic
Genetic and Kidney Cyst Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Caring for Australians and New ZealandeRs with kidney Impairment guideline commentary on kidney disease: improving global outcomes 2025 guidelines for diagnosis and management of autosomal polycystic kidney disease

Amali Mallawaarachchi, Andrew John Mallett, Kelly Lambert, Jessica Dawson et al.
Internal Medicine Journal
Genetic and Kidney Cyst Diseases
article

Caring for Australians and New ZealandeRs with kidney Impairment guideline commentary on kidney disease: improving global outcomes 2025 guidelines for diagnosis and management of autosomal polycystic kidney disease

Amali Mallawaarachchi, Andrew John Mallett, Kelly Lambert, Jessica Dawson, V WS Lee, Stephen I. Alexander, Judy Savige, Brydee Cashmore, Kitty St Pierre, Mia E. Abdy, David J. Tunnicliffe, Gopala Rangan, Emily Major, Helen Coolican, Vanessa Cullen, Santosh Varughese
article en

Abstract

Autosomal polycystic kidney disease (ADPKD) is the most common form of inherited kidney disease. The international guideline developer, Kidney Disease: Improving Global Outcomes (KDIGO), published a 2025 clinical practice guideline reflecting advances in genetic testing and the first disease-modifying agent, tolvaptan. However, KDIGO guidelines do not address healthcare access or equity issues relevant to the needs of our populations in Australia and New Zealand. The Caring for Australians and New ZealandeRs with kidney Impairment (CARI) Guidelines Working Group has provided a regional commentary to contextualise the KDIGO 2025 ADPKD guideline. This commentary aims to support clinicians in applying the KDIGO ADPKD 2025 guidance within our local health systems and highlights challenges in the implementation, including public subsidy limitations for recommended genetic testing and treatments. It also addresses equity concerns such as rural and remoteness, ensuring guidance is relevant to Australia and New Zealand.

Internal Medicine Journal
Griffith University (AU), The University of Sydney (AU), The Royal Melbourne Hospital (AU), Garvan Institute of Medical Research (AU), The University of Queensland (AU), La Trobe University (AU), University of Wollongong (AU), Gold Coast Hospital (AU), Townsville Hospital (AU), Children's Hospital at Westmead (AU), Westmead Hospital (AU), Illawarra Health and Medical Research Institute (AU), St George Hospital (AU), Westmead Institute (AU), Sydney Local Health District (AU), Westmead Institute for Medical Research (AU), National Health and Medical Research Council (AU), James Cook University (AU)
Partnerships for the goals
Openalex Percentile: Top 12%
Genetic and Kidney Cyst Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.